CN114469849A - 一种温敏水凝胶封装线粒体的应用 - Google Patents
一种温敏水凝胶封装线粒体的应用 Download PDFInfo
- Publication number
- CN114469849A CN114469849A CN202210040400.XA CN202210040400A CN114469849A CN 114469849 A CN114469849 A CN 114469849A CN 202210040400 A CN202210040400 A CN 202210040400A CN 114469849 A CN114469849 A CN 114469849A
- Authority
- CN
- China
- Prior art keywords
- mitochondria
- hydrogel
- encapsulated
- temperature
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 45
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 44
- 238000005538 encapsulation Methods 0.000 title description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 7
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 230000003680 myocardial damage Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 abstract description 21
- 238000002054 transplantation Methods 0.000 abstract description 19
- 230000002438 mitochondrial effect Effects 0.000 abstract description 17
- 210000004165 myocardium Anatomy 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 229940126585 therapeutic drug Drugs 0.000 abstract description 3
- 206010019280 Heart failures Diseases 0.000 abstract description 2
- 230000008602 contraction Effects 0.000 abstract description 2
- 230000003111 delayed effect Effects 0.000 abstract description 2
- 230000037149 energy metabolism Effects 0.000 abstract description 2
- 208000037891 myocardial injury Diseases 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 6
- 229960003699 evans blue Drugs 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 230000004217 heart function Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000592 Artificial Cell Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 230000030544 mitochondrion distribution Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种温敏水凝胶封装线粒体的应用，属于生物医药技术领域。本发明提供一种温敏水凝胶封装线粒体在制备预防或治疗心肌损伤的药物上的应用和在制备预防或治疗心肌缺血再灌注损伤的药物上的应用；温敏水凝胶封装线粒体作为体内移植物的应用；温敏水凝胶通过封装线粒体输送至目标区域，在制备预防或治疗性药物上的应用。本发明通过使用亲水性能佳、生物相容性良好的水凝胶作为线粒体移植的载体，从而增加心肌细胞对线粒体的摄取率，改善缺血心肌细胞的能量代谢和机械收缩与舒张功能，延缓心衰的发生。通过本发明能够叠加水凝胶改善损伤心肌力学微环境和线粒体移植的效果，具有重要的临床推广与应用价值。
Description
技术领域
本发明涉及一种温敏水凝胶封装线粒体的应用，属于生物医药技术领域。
背景技术
线粒体是真核细胞获取能量支撑的主要动力工厂，心脏作为高耗能器官，心肌对于线粒体代谢的依赖性尤其显著。心肌缺血及再灌注损伤是临床亟待解决的关键问题，心肌细胞的存活率直接决定了心肌梗死面积和修复后心脏的功能及恶化程度，当前多个研究已证实，结构完整、具有活性的线粒体进行移植能够抑制心肌损伤，改善心脏功能，80％的外源性线粒体会在很短的时间内被心肌细胞迅速吸收内化，改善细胞的呼吸功能，增加ATP的生成，并且经研究显示，移植线粒体最长能在28天后仍然发挥保护作用，但是，线粒体的吸收效率和在损伤心肌的分布仍然受到移植方式的影响，尽管目前一些研究者试图通过特异性分子靶向递送，但其临床效果仍有待检验，线粒体移植的临床转化还有诸多工作需要进行。
新兴的高分子材料水凝胶近年来被广泛应用于医疗领域，是一种绝佳的药物、外泌体、干细胞等物质的载体，同时，水凝胶本身也具有一定的治疗作用。水凝胶是天然的或者人工合成的大分子与水分子的交联网络，新型可注射智能水凝胶具有良好的生物相容性，具有模拟细胞外基质的特性，并且能在一定时间内降解，一般降解产物也没有生物毒性。在心脏疾病领域已有多种形式的水凝胶用于临床治疗，例如正在进行临床试验的VentriGel等。研究表明，水凝胶发挥治疗作用的方式可能是通过打断基质降解，影响力学环境的恶性循环、促进血管新生和细胞归巢等机制发挥了保护作用，而作为载体又能大大提高干细胞、质粒等在心肌局部的移植植入率。水凝胶封装线粒体能够为线粒体提供类细胞及基质环境，并且有研究证实水凝胶封装线粒体可作为人工细胞的制备基础，只是目前尚没有水凝胶作为线粒体移植载体的相关报道。
发明内容
本发明的目的是为解决线粒体如何移植以治疗心肌缺血再灌注损伤的技术问题。
为达到解决上述问题的目的，本发明所采取的技术方案是提供一种温敏水凝胶封装线粒体在制备预防或治疗心肌损伤的药物上的应用。
本发明提供一种温敏水凝胶封装线粒体在制备预防或治疗心肌缺血再灌注损伤的药物上的应用。
本发明提供一种温敏水凝胶封装线粒体在非诊断方法或非治疗方法上的应用。
优选地，所述温敏水凝胶封装线粒体作为体内移植物。
本发明提供一种温敏水凝胶在制备预防或治疗性药物上的应用，所述温敏水凝胶通过封装线粒体输送至目标区域。
相比现有技术，本发明具有如下有益效果：
本发明通过使用亲水性能佳、生物相容性良好的水凝胶作为线粒体移植的载体，从而增加心肌细胞对线粒体的摄取率，改善缺血心肌细胞的能量代谢和机械收缩与舒张功能，延缓心衰的发生。通过本发明能够叠加水凝胶改善损伤心肌力学微环境和线粒体移植的效果，具有重要的临床推广与应用价值。
附图说明
图1为通过超声心动图检测水凝胶封装线粒体移植对缺血再灌注损伤小鼠心功能的改善效果图。
图2为通过Evan‘s blue/TTC染色评估水凝胶封装线粒体移植后缺血再灌注损伤小鼠心脏梗死面积结果图。
图3为通过HE染色评估水凝胶封装线粒体移植对缺血再灌注损伤小鼠心肌炎性细胞浸润和病理结构的影响图。
图4为通过WB评估水凝胶封装线粒体移植对缺血再灌注损伤小鼠心肌凋亡的影响图。
具体实施方式
为使本发明更明显易懂，兹以优选实施例，并配合附图作详细说明如下：
如图1-4所示，本发明所采取的技术方案是提供一种温敏水凝胶封装线粒体在制备预防或治疗心肌损伤的药物上的应用。
本发明提供一种温敏水凝胶封装线粒体在制备预防或治疗心肌缺血再灌注损伤的药物上的应用。
本发明提供一种温敏水凝胶封装线粒体在非诊断方法或非治疗方法上的应用。温敏水凝胶封装线粒体作为体内移植物。
本发明提供一种温敏水凝胶在制备预防或治疗性药物上的应用，所述温敏水凝胶通过封装线粒体输送至目标区域。
实施例
1.用生理盐水将Pluronic F127粉末(Sigma公司，)配制成15％(w/w％)的水凝胶，低温保存。
2.获得C57BL/6小鼠心肌，应用线粒体分离试剂盒(碧云天生物技术有限公司，C3606)将心肌经酶消化、线粒体分离试剂重悬后适当研磨，1000g、4℃离心5分钟，取上清，转移到新的EP管中，继续离心(3500g、4℃、10min)获得纯化线粒体，使用15％w/w的Pluronic F127温敏水凝胶在0-4℃低温环境中重悬，摇床缓慢混匀5-10min，备用。以上皆为无菌操作。
3.制备小鼠的心肌缺血再灌注损伤模型(缺血45min,再灌注24小时)，在再灌注时沿心肌乳头肌方向分3个位点分别注射25ul微升水凝胶封装的线粒体(5-10×104个/ml)；对照组实施假手术：缺血再灌注损伤组只注射相同体积的生理盐水。灌注24小时后行超声心动图检测小鼠心脏功能，Evans blue/TTC染色检测小鼠心肌的梗死面积，HE染色检测心肌组织损伤程度及炎症细胞浸润情况。
实验结果：
如图1所示：为通过超声心动图检测水凝胶封装线粒体移植对缺血再灌注损伤小鼠心功能的改善效果图；图中：IR组代表缺血再灌注损伤模型组；IRFM组代表F127水凝胶封装线粒体进行心肌注射的小鼠治疗组；WT代表实施假手术的对照组；
如图中超声心动图显示水凝胶辅助线粒体移植组的缺血再灌注损伤小鼠心脏左室射血分数显著增加(P＜0.05)。
如图2所示为通过Evan‘s blue/TTC染色评估水凝胶封装线粒体移植后缺血再灌注损伤小鼠心脏梗死面积结果图。图中IR组代表缺血再灌注损伤模型组；IRFM组代表F127水凝胶封装线粒体进行心肌注射的小鼠治疗组；IRM代表实施线粒体进行心肌注射的小鼠治疗组；图中白色为心肌梗死区(不能被Evans blue和TTC染液染色)，红色为心肌缺血区(不能被Evans blue但能被TTC染色)，蓝色为非缺血区(被Evans blue和TTC染液染色)。
图3为通过HE染色评估水凝胶封装线粒体移植对缺血再灌注损伤小鼠心肌炎性细胞浸润和病理结构的影响图。其中WT代表实施假手术的对照组；IR组代表缺血再灌注损伤模型组；IRM代表实施线粒体直接进行心肌注射的小鼠治疗组；IRF代表实施F127水凝胶直接进行心肌注射的小鼠治疗组；IRFM组代表F127水凝胶封装线粒体进行心肌注射的小鼠治疗组；图中HE染色中红色为胞浆染色，蓝色为细胞核，从图中可见损伤模型组大量炎症细胞浸润，水凝胶辅助线粒体移植组IRFM组的炎症细胞浸润显著减轻。
图4为通过WB评估水凝胶封装线粒体移植对缺血再灌注损伤小鼠心肌凋亡的影响图。其中WT代表实施假手术的对照组；IR组代表缺血再灌注损伤模型组；IRM代表实施线粒体直接进行心肌注射的小鼠治疗组；IRF代表实施F127水凝胶直接进行心肌注射的小鼠治疗组；IRFM组代表F127水凝胶封装线粒体进行心肌注射的小鼠治疗组；从图中可见水凝胶辅助线粒体移植组IRFM组的心肌凋亡显著减轻。
以上所述，仅为本发明的较佳实施例，并非对本发明任何形式上和实质上的限制，应当指出，对于本技术领域的普通技术人员，在不脱离本发明的前提下，还将可以做出若干改进和补充，这些改进和补充也应视为本发明的保护范围。凡熟悉本专业的技术人员，在不脱离本发明的精神和范围的情况下，当可利用以上所揭示的技术内容而做出的些许更动、修饰与演变的等同变化，均为本发明的等效实施例；同时，凡依据本发明的实质技术对上述实施例所作的任何等同变化的更动、修饰与演变，均仍属于本发明的技术方案的范围内。
Claims (5)
1.一种温敏水凝胶封装线粒体在制备预防或治疗心肌损伤的药物上的应用。
2.一种温敏水凝胶封装线粒体在制备预防或治疗心肌缺血再灌注损伤的药物上的应用。
3.一种温敏水凝胶封装线粒体在非诊断方法或非治疗方法上的应用。
4.如权利要求3所述的一种温敏水凝胶封装线粒体在非诊断方法或非治疗方法上的应用，其特征在于，所述温敏水凝胶封装线粒体作为体内移植物。
5.一种温敏水凝胶在制备预防或治疗性药物上的应用，其特征在于，所述温敏水凝胶通过封装线粒体输送至目标区域。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210040400.XA CN114469849B (zh) | 2022-01-14 | 2022-01-14 | 一种温敏水凝胶封装线粒体的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210040400.XA CN114469849B (zh) | 2022-01-14 | 2022-01-14 | 一种温敏水凝胶封装线粒体的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114469849A true CN114469849A (zh) | 2022-05-13 |
| CN114469849B CN114469849B (zh) | 2024-10-18 |
Family
ID=81512381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210040400.XA Active CN114469849B (zh) | 2022-01-14 | 2022-01-14 | 一种温敏水凝胶封装线粒体的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114469849B (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288779A (zh) * | 2007-04-18 | 2008-10-22 | 中国人民解放军军事医学科学院基础医学研究所 | 基于温敏性壳聚糖水凝胶的可注射性心肌组织工程产品 |
| US20140105960A1 (en) * | 2012-10-12 | 2014-04-17 | Children's Medical Center Corporation | Hydrogels for tissue regeneration |
| US20170196818A1 (en) * | 2014-06-30 | 2017-07-13 | President And Fellows Of Harvard College | Hydrogel compositions comprising encapsulated cells and methods of use thereof |
| US20200009198A1 (en) * | 2016-11-30 | 2020-01-09 | Paean Biotechnology Inc. | Pharmaceutical compostion containing mitochondria |
| CN111419876A (zh) * | 2020-04-30 | 2020-07-17 | 复旦大学附属中山医院 | 线粒体移植在治疗原发性扩心病中的应用 |
| WO2020222866A1 (en) * | 2019-05-02 | 2020-11-05 | Children's Medical Center Corporation | Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents |
-
2022
- 2022-01-14 CN CN202210040400.XA patent/CN114469849B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288779A (zh) * | 2007-04-18 | 2008-10-22 | 中国人民解放军军事医学科学院基础医学研究所 | 基于温敏性壳聚糖水凝胶的可注射性心肌组织工程产品 |
| US20140105960A1 (en) * | 2012-10-12 | 2014-04-17 | Children's Medical Center Corporation | Hydrogels for tissue regeneration |
| US20170196818A1 (en) * | 2014-06-30 | 2017-07-13 | President And Fellows Of Harvard College | Hydrogel compositions comprising encapsulated cells and methods of use thereof |
| US20200009198A1 (en) * | 2016-11-30 | 2020-01-09 | Paean Biotechnology Inc. | Pharmaceutical compostion containing mitochondria |
| WO2020222866A1 (en) * | 2019-05-02 | 2020-11-05 | Children's Medical Center Corporation | Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents |
| CN111419876A (zh) * | 2020-04-30 | 2020-07-17 | 复旦大学附属中山医院 | 线粒体移植在治疗原发性扩心病中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| MUNIR BOODHWANI: "Effects of purified poloxamer 407 gel on vascular occlusion and the coronary endothelium", 《 EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY》, vol. 29, no. 5, 1 May 2006 (2006-05-01), pages 740 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114469849B (zh) | 2024-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105209014B (zh) | 含有肉毒杆菌神经毒素的药物组合物及其应用 | |
| US20160310544A1 (en) | Methods And Compositions For Regenerating And Repairing Damaged Or Aged Tissue Or Organs Using Nonviable Irradiated Or Lyophilized Pluripotent Stem Cells | |
| RU2012104650A (ru) | Кондиционированная среда и композиции на основе внеклеточного матрикса из клеток, культивированных в гипоксических условиях | |
| Li et al. | Bioactive MXene promoting angiogenesis and skeletal muscle regeneration through regulating M2 polarization and oxidation stress | |
| Kastrup | Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome? | |
| WO2023221152A1 (zh) | 具有心脏损伤修复功能的智能水凝胶及其制备方法和应用 | |
| Wu et al. | Injectable polyaniline nanorods/alginate hydrogel with AAV9-mediated VEGF overexpression for myocardial infarction treatment | |
| WO2023072161A1 (zh) | 包含间充质干细胞和水凝胶的组合物及其应用 | |
| KR20240028370A (ko) | 3차원 배양된 탯줄 유래 중간엽 줄기세포 및 이의 용도 | |
| Broughton et al. | Myocardial Regeneration for Humans―Modifying Biology and Manipulating Evolution― | |
| Xue et al. | Recent advances of exosomes in soft tissue injuries in sports medicine: A critical review on biological and biomaterial applications | |
| Zhao et al. | Therapeutic effect of human umbilical cord mesenchymal stem cells in early traumatic osteonecrosis of the femoral head | |
| Xu et al. | Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction | |
| Schuldt et al. | Repairing damaged myocardium: evaluating cells used for cardiac regeneration | |
| RU2005102061A (ru) | Среда для культивирования аутологических человеческих стволовых клеток-предшественников и способы их применения | |
| CN114469849B (zh) | 一种温敏水凝胶封装线粒体的应用 | |
| Huang et al. | Transplantation of mitochondria encapsulated in hydrogel ameliorates myocardial ischemia-reperfusion injury | |
| CN109864964B (zh) | 一种包含干细胞的抗衰老组合物及其应用 | |
| US20240115627A1 (en) | Use of clostridium ghonii spore combined with pembrolizumab | |
| CN114404450B (zh) | 一种温敏型干细胞外泌体即型凝胶 | |
| KR102445484B1 (ko) | 장 오가노이드 제조용 배지 조성물 | |
| CN114451397B (zh) | 用于保存干细胞的凝胶制剂及其制备方法以及含有凝胶制剂和干细胞的药物组合物 | |
| KR102250231B1 (ko) | 심혈관 질환 예방 또는 치료용 조성물 | |
| CN111481659B (zh) | Ⅱ型胶原和透明质酸复合凝胶液及制备方法和用途 | |
| CN110141679B (zh) | 一种缓释心肌补片材料及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230918 Address after: 231100 southeast corner of the intersection of Huainan North Road and Huaihai Avenue, Changfeng Shuangfeng Economic Development Zone, Hefei City, Anhui Province Applicant after: Kangnuo Biopharmaceutical Co.,Ltd. Address before: 200032 No. 136, Xuhui District Medical College, Shanghai Applicant before: ZHONGSHAN HOSPITAL, FUDAN University |
|
| GR01 | Patent grant |